Pharvaris (NASDAQ:PHVS - Get Free Report) shares reached a new 52-week low on Wednesday . The company traded as low as $11.76 and last traded at $11.83, with a volume of 20599 shares trading hands. The stock had previously closed at $13.21.
Analysts Set New Price Targets
Separately, JMP Securities raised their price objective on shares of Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a report on Friday, January 31st.
Read Our Latest Stock Analysis on Pharvaris
Pharvaris Stock Performance
The stock has a 50-day moving average of $15.55 and a two-hundred day moving average of $18.36. The company has a market cap of $638.20 million, a P/E ratio of -4.36 and a beta of -2.84.
Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its earnings results on Monday, April 7th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.06. As a group, sell-side analysts forecast that Pharvaris will post -2.71 EPS for the current fiscal year.
Hedge Funds Weigh In On Pharvaris
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio bought a new stake in shares of Pharvaris in the third quarter worth about $57,000. JPMorgan Chase & Co. raised its holdings in shares of Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after acquiring an additional 2,847 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Pharvaris in the fourth quarter worth $64,000. Barclays PLC bought a new position in Pharvaris in the 3rd quarter worth $106,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Pharvaris in the 4th quarter worth about $111,000.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
See Also
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
